Cochrane · systematic review · CD003047
Dopamine agents for hepatic encephalopathy
Junker, AE, Als‐Nielsen, B, Gluud, C, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
2
current version
GRADE rated
2
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Dopamine agonists for hepatic encephalopathy
Population: patients with hepatic encephalopathy.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality | OR 1.11 [0.35, 3.54] | 144 participants | Low Downgraded: risk of bias, imprecision, publication bias |
Hepatic encephalopathy | OR 2.99 [0.09, 100.55] | 80 participants | Low Downgraded: risk of bias, imprecision, publication bias |